When generics turn into Big Pharma

Top generics firms, some from India, are charged with price-fixing and sleazy deals; Sun Pharma has paid up to settle claims  

COVID-19 also brings focus back on pollution due to pharmaceuticals

No time for quick-fix measures. India needs stricter laws  

COVID-19 underlines medicine interdependency, which is not good: Experts

Countries must come out of global value chain and become self-dependent, they said

Look back at the decade: Generic drugs

Fifteen years after it rose and went limp, the biotech sector saw a bull run of sorts

Pills by jugaad: Excerpts from Bottle of Lies

A new investigative book, Bottle of Lies, says that Indian cancer drugs are contaminated; cholesterol medication has shards of glass; and, blood …

Six reasons why antibiotics access remains a challenge in Uganda

Lack of registry, sub-standard health facilities, poor cold storage, limited expenditure on health, irrational antibiotic use and lack of …

Colour code for generic medicines a no-brainer

There are a number of systemic gaps without addressing which the government’s latest plan for the pharma sector won’t work

Beware of Japan's trade ambitions

Japan is pushing for higher levels of intellectual property protection that will cut access to affordable medicines

This is why Hepatitis B, Hepatitis C are dangerous

Just one in 10 infected know their status and many are unaware that the inflamation of the liver is a common and treatable disease

Civil society challenges patents on Hepatitis C drugs

Pharmaceutical corporations obtain unjustified patents making the drugs unaffordable to many, petitioners claim  

Highlights of 2016 International AIDS Conference in South Africa

South Africa has the highest infection rate in the world with about seven million affected

Gilead signs agreements with Indian generic companies for hepatitis C drug

Indian companies granted licence to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment …

US keeps India out of Priority Foreign Country list of 'worst IP offenders'

US Trade Representative’s Special 301 Report keeps up pressure on India to fall in line with US’ interests

Novartis loses patent appeal in landmark suit

Supreme Court upholds amended law that bars patents for insignificant improvements to an existing drug—in this case anti-cancer drug …

Government stand against EU ban on Indian drugs much needed, says industry

Standing against the arbitrary ban on 700 drugs, India has decided to defer the proposed talks on the free trade agreement between India and the EU

Generic drugs needed to eliminate Hepatitis C, say experts

Currently, medicines available to treat patients are exorbitantly priced

Ranbaxy effect: Indian government defends pharma industry

Few isolated cases cannot undermine well regulated system, says commerce ministry

Profits and not improving accessibility matter to Indian drug makers

FICCI conference organised to discuss access to generic medicines focuses more on increasing exports

AAP promises to improve health set-up and promote generic medicines in Delhi

Party says it will address health concerns of both the elderly and the young if it is voted to power

Activists demand compulsory licence for another life-saving cancer drug

Appellate board's order upholding Natco's CL for sorafenib tosylate may pave way for manufacture of generic version of other patented drugs

EU fines nine pharma companies for violating competition rules

Lundbeck pharma made other companies enter market late with generic versions of its drug citalopram

Vidarbha gets its first generic medicines shop

Challenge to popularising these stores is to get doctors to prescribe low-cost generic drugs

European Parliament rejects Anti-Counterfeiting Trade Agreement

Act makes it possible to seize and destroy even legitimately produced generic drugs exported from India to poor countries

Substantiate allegations against Ranbaxy, says Supreme Court

Experts say allegations against the generic pharma company motivated by vested interests

‘PESTICIDES’ IN DRUGS

Sharad Pawar’s provision for protecting test data in the Pesticides Bill could spill over into trade agreements and hit the drugs industry, too